Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1914533 | 0.98 | L3MBTL1 (0.54) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL7614766 | 0.86 | L3MBTL1 (0.45) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL7614772 | 0.84 | L3MBTL1 (0.43) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL12272001 | 0.78 | MAPK9 (0.40) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL10094582 | 0.77 | MAPK9 (0.43) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL4973497 | 0.77 | L3MBTL1 (0.58) | L3MBTL1SMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL16815410 | 0.76 | L3MBTL1 (0.56) | L3MBTL1SMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL28239177 | 0.76 | GAA (0.43) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL1914614 | 0.74 | L3MBTL1 (0.44) | L3MBTL1SMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL30388994 | 0.74 | HTT (0.44) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730683-B2 | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses | SMITHKLINE BEECHAM CORPORATION | 2004-05-04 | — | — | US | disclosed |
| EP-0996446-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6562832-B1 | Cytokine suppressive anti-inflammatory drugs, capable of inhibiting the CSBP/p38/RK kinase | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| US-20020198206-A1 | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses | SMITHKLINE BEECHAM CORPORATION | 2002-12-26 | — | — | US | disclosed |
| EP-1037639-A4 | COMPOUNDS OF HETEROARYL SUBSTITUTED IMIDAZOLE, THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SMITHKLINE BEECHAM CORP (US) | 2002-04-17 | — | — | EP | disclosed |
| US-6335340-B1 | REACTING POLYMER BOUND 2-THIOPYRIMIDINE-4-YL IMINE WITH AN ISONITRILE; OXIDATION TO SULFONE OR SULFOXIDE TO RELEASE; AMINATION; ADMINISTERING AS CYTOKINE, INTERLEUKIN, AND TUMOR NECROSIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2002-01-01 | — | — | US | disclosed |
| EP-0996446-A4 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6251914-B1 | TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-06-26 | — | — | US | disclosed |
| EP-1037639-A1 | COMPOUNDS OF HETEROARYL SUBSTITUTED IMIDAZOLE, THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-09-27 | — | — | EP | disclosed |
| EP-1019396-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SmithKline Beecham Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0996446-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-03 | — | — | EP | disclosed |
| US-6046208-A | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, ENDOTOXEMIA AND/OR TOXIC SHOCK SYNDROME, OTHER ACUTE OR CHRONIC INFLAMMATORY DISEASE STATES SUCH AS THE INFLAMMATORY REACTION INDUCED BY ENDOTOXIN OR INFLAMMATORY BOWEL DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1999032121-A1 | COMPOUNDS OF HETEROARYL SUBSTITUTED IMIDAZOLE, THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999001131-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |
| WO-1999001452-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198206-A1 | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses | IL2, IFNG, IL2RA | L3MBTL1 4867/4885SMN1; SMN2 4408/4885MAPK9 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.